6.25 -0.05 (-0.86%)
After hours: 4:10PM EDT
|Bid||6.25 x 800|
|Ask||6.30 x 3200|
|Day's Range||6.00 - 6.45|
|52 Week Range||5.10 - 11.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.63|
Aduro Biotech, Inc. (ADRO) today announced that Natalie R. Sacks, M.D. has resigned from her position as the company’s chief medical officer effective October 1, 2018. “On behalf of the management team and Board of Directors, I’m grateful for the significant contributions Natalie made over the past three years and we wish her the best in her next endeavor,” commented Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “During her tenure, Natalie has played an integral role in defining the development strategy for our lead STING agonist ADU-S100 and for our anti-APRIL antibody BION-1301, two first-in-class assets that have potential to impact the treatment landscape for patients with a myriad of serious diseases.
Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. Aduro BioTech’s insiders have divested from 53.11k sharesRead More...
Aduro Biotech, Inc. (ADRO) today announced the publication of a peer reviewed paper in Leukemia authored by scientists from the Dana Farber Cancer Institute and Aduro as part of their ongoing collaboration to study the role of APRIL (A PRoliferation Inducing Ligand) in multiple myeloma (MM). The authors profile the impact that APRIL, acting through its receptor TACI (transmembrane activator and cyclophilin ligand interactor), has on immune regulatory T cells (Tregs) in MM. The paper further reports that APRIL binding to TACI contributes to the immunosuppressive and treatment resistant MM bone marrow microenvironment, an effect that could potentially be mitigated by anti-APRIL antibody, BION-1301.
Aduro Biotech, Inc. (ADRO) today announced that preclinical data for its first-in-class anti-APRIL antibody BION-1301 was presented at the 5th European Congress of Immunology in Amsterdam, The Netherlands. Data from the preclinical studies demonstrated that BION-1301 was well-tolerated. In addition, pharmacological activity of BION-1301 binding to APRIL (A Proliferation-Inducing Ligand), a ligand for the receptors BCMA (B cell maturation antigen) and TACI (transmembrane activator and cyclophilin ligand interactor), was established in a dose-dependent fashion.
Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aduro Biotech, Inc. (ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present at the 20th Annual H.C. Wainwright Global Investment Conference in New York, NY on Wednesday, September 5, 2018 at 1:45pm Eastern Time. To access the live webcast and subsequent archived recording of this and other company presentations, please visit Aduro's website at www.aduro.com. Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that are intended to transform the treatment of challenging diseases.
NEW YORK, Aug. 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clearwater ...
Aduro Biotech (ADRO) delivered earnings and revenue surprises of 6.06% and -29.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Berkeley, California-based company said it had a loss of 31 cents. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
BERKELEY, Calif., Aug. 01, 2018-- Aduro Biotech, Inc. today reported financial results for the second quarter ended June 30, 2018. Net loss for the second quarter of 2018 was $24.4 million, or $0.31 per ...
LONDON, UK / ACCESSWIRE / July 26, 2018 / If you want a free Stock Review on ADXS sign up now at www.wallstequities.com/registration. On Wednesday, July 25, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories.
NEW YORK, June 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Newfield ...
Featured today on WallStEquities.com is the Biotechnology industry, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are four equities: Adaptimmune Therapeutics PLC (NASDAQ: ADAP), Aduro BioTech Inc. (NASDAQ: ADRO), Advaxis Inc. (NASDAQ: ADXS), and Adverum Biotechnologies Inc. (NASDAQ: ADVM).
Aduro (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aduro's (ADRO) loss in Q1 narrows from the estimate. Moreover, revenues top the same and surge substantially year over year on receipt of a milestone payment.
On a per-share basis, the Berkeley, California-based company said it had a loss of 28 cents. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Three Chinese funds are backing this San Francisco startup that looks to tap some of the emerging areas of cancer immunotherapy.